Clinical Trial Update: Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating imatinib mesylate with or without surgery for metastatic gastrointestinal stromal tumor that responds to imatinib has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Gastrointestinal Stromal Tumor | Phase 3 | Status: TERMINATED